Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05451004 · ClinicalTrials.gov registry record · Phase 3
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
A Phase 3 study of Oropharyngeal Cancer, sponsored by Canadian Cancer Trials Group.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 510
- Enrollment target
- 20
- Study locations
NCT05451004: Recruiting Phase 3 study of Oropharyngeal Cancer, sponsored by Canadian Cancer Trials Group.
NCT05451004 is a Phase 3 study of Oropharyngeal Cancer that is actively recruiting participants, run by Canadian Cancer Trials Group. The registered enrollment target is 510 participants, above the 169-participant average among 25 other Oropharyngeal Cancer trials with a reported enrollment target (202% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05451004, a Phase 3 study of Oropharyngeal Cancer, is actively recruiting participants, sponsored by Canadian Cancer Trials Group.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 510 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SPECT-CT), compared to the usual treatment when radiotherapy is given to both sides of the neck?
Conditions Studied
Interventions
- OTHER Lymphatic Mapping with SPECT-CT
- RADIATION Ipsilateral and Contralateral Neck
Study Locations (20)
Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables - Coral Gables
- Baptist MD Anderson Cancer Center - Jacksonville
- University of Miami Miller School of Medicine-Sylvester Cancer Center - Miami
- Moffitt Cancer Center-International Plaza - Tampa
- Moffitt Cancer Center - McKinley Campus - Tampa
- Moffitt Cancer Center - Tampa
Michigan
- University of Michigan Rogel Cancer Center - Ann Arbor
- University of Michigan - Brighton Center for Specialty Care - Brighton
- Henry Ford Hospital - Detroit
California
- City of Hope Corona - Corona
- City of Hope Comprehensive Cancer Center - Duarte
Illinois
- Northwestern University - Chicago
- Northwestern Medicine Cancer Center Warrenville - Warrenville
Texas
- MD Anderson in The Woodlands - Conroe
- M D Anderson Cancer Center - Houston
Georgia
- Emory University Hospital Midtown - Atlanta
Kentucky
- The James Graham Brown Cancer Center at University of Louisville - Louisville
Missouri
- MU Health - University Hospital/Ellis Fischel Cancer Center - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2023-02-10 |
| Est. Completion | 2031-08-30 |
| Phase | Phase 3 |
What NCT05451004 shows while recruiting
NCT05451004 is an interventional study that assigns participants to a tested intervention. The registered 510 participants enrollment target is mid-sized for trials with a published cap, above the 169-participant average among 25 other Oropharyngeal Cancer trials with a reported enrollment target (202% higher).
The record links to 1 condition, with Oropharyngeal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Lymphatic Mapping with SPECT-CT is the first listed.
NCT05451004 names 20 study sites across 10 states, led by Florida, Michigan, California.
Frequently Asked Questions
What is clinical trial NCT05451004 about?
NCT05451004 is a clinical study titled "SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer". This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SPECT-CT), compared to...
What is the current status of trial NCT05451004?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 510 participants. The study started on 2023-02-10. Estimated completion is 2031-08-30.
What conditions does trial NCT05451004 study?
This clinical trial studies the following conditions: Oropharyngeal Cancer.
What interventions are being tested in trial NCT05451004?
The interventions under investigation include: Lymphatic Mapping with SPECT-CT (OTHER), Ipsilateral and Contralateral Neck (RADIATION).
Who is sponsoring clinical trial NCT05451004?
This trial is sponsored by Canadian Cancer Trials Group, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05451004 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oropharyngeal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05451004's enrollment target sits among peer trials
510 3rd of 25 higher than 23 of 25 other Oropharyngeal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Oropharyngeal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)
RECRUITING
-
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
RECRUITING · Phase 2
-
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
RECRUITING · Phase 2
-
A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)
RECRUITING · Phase 2
-
Liposomal Bupivacaine and Transoral Robotic Surgery
RECRUITING
-
Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03922542 · 510 participants · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
- NCT04634552 · 510 participants · Phase 2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- NCT05164744 · 510 participants
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
- NCT05561387 · 510 participants · Phase 3
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI